Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)

LESSONS LEARNED: The combination of carotuximab with axitinib did not provide a benefit over axitinib monotherapy in patients with metastatic clear cell renal cell carcinoma who had previously progressed on one or more vascular endothelial growth factor (VEGF)‐targeted therapies. Exploratory evaluat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Choueiri, Toni K., Zakharia, Yousef, Pal, Sumanta, Kocsis, Judit, Pachynski, Russell, Poprach, Alexandr, Nixon, Andrew B., Liu, Yingmiao, Starr, Mark, Lyu, Jing, Owzar, Kouros, deShazo, Mollie, Lara, Primo, Geczi, Lajos, Ho, Thai H., Walsh, Meghara, Adams, Bonne, Robertson, Liz, Darif, Mohamed, Theuer, Charles, Agarwal, Neeraj
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2021
Témata:
Clinical Trial Results
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8265348/
https://ncbi.nlm.nih.gov/pubmed/33829609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13777
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky